Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · IEX Real-Time Price · USD
41.59
-0.25 (-0.60%)
At close: Apr 26, 2024, 4:00 PM
40.34
-1.25 (-3.01%)
After-hours: Apr 26, 2024, 7:57 PM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees on February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$849,673
Profits / Employee
-$395,131
Market Cap
6.06B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Feb 15, 2024 | 927 | 131 | 16.46% |
| Feb 16, 2023 | 796 | 136 | 20.61% |
| Feb 16, 2022 | 660 | -97 | -12.81% |
| Feb 18, 2021 | 757 | -60 | -7.34% |
| Feb 20, 2020 | 817 | 80 | 10.85% |
| Feb 20, 2019 | 737 | 190 | 34.73% |
| Feb 20, 2018 | 547 | 112 | 25.75% |
| Feb 21, 2017 | 435 | 7 | 1.64% |
| Feb 19, 2016 | 428 | 38 | 9.74% |
| Feb 17, 2015 | 390 | 86 | 28.29% |
| Feb 17, 2014 | 304 | 16 | 5.56% |
| Feb 11, 2013 | 288 | 7 | 2.49% |
| Feb 13, 2012 | 281 | 11 | 4.07% |
| Feb 14, 2011 | 270 | 20 | 8.00% |
| Feb 10, 2010 | 250 | -50 | -16.67% |
| Feb 10, 2009 | 300 | 0 | - |
| Mar 1, 2008 | 300 | 26 | 9.49% |
| Mar 5, 2007 | 274 | 16 | 6.20% |
| Mar 3, 2006 | 258 | -45 | -14.85% |
| Mar 3, 2005 | 303 | -154 | -33.70% |
| Mar 3, 2004 | 457 | -66 | -12.62% |
| Feb 28, 2003 | 523 | 89 | 20.51% |
| Feb 28, 2002 | 434 | 131 | 43.23% |
| Jan 31, 2001 | 303 | -49 | -13.92% |
| Feb 25, 2000 | 352 | 6 | 1.73% |
| Feb 26, 1999 | 346 | 8 | 2.37% |
| Feb 27, 1998 | 338 | 51 | 17.77% |
| Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| The Ensign Group | 35,300 |
| Grifols | 23,737 |
| Acadia Healthcare Company | 23,500 |
| DENTSPLY SIRONA | 15,000 |
| Bausch + Lomb | 13,300 |
| Elanco Animal Health | 9,800 |
| Apellis Pharmaceuticals | 702 |
| Blueprint Medicines | 655 |
IONS News
- 2 days ago - Ionis Publishes 2023 Corporate Responsibility Report - PRNewsWire
- 4 days ago - Ionis to hold first quarter 2024 financial results webcast - PRNewsWire
- 20 days ago - Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome - PRNewsWire
- 26 days ago - Ionis to present at upcoming investor conferences - PRNewsWire
- 4 weeks ago - Ionis to hold olezarsen Phase 3 data webcast - PRNewsWire
- 4 weeks ago - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting - PRNewsWire
- 6 weeks ago - Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial - Reuters
- 6 weeks ago - Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH - PRNewsWire